A Comparison of the Effects of Carvedilol and Metoprolol on Well-Being, Morbidity, and Mortality (the “Patient Journey”) in Patients With Heart Failure-Reference-Cited by-同舟云学术

A Comparison of the Effects of Carvedilol and Metoprolol on Well-Being, Morbidity, and Mortality (the “Patient Journey”) in Patients With Heart Failure

Published:2006-04 Issue:8 Volume:47 Page:1603-1611
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Cleland John G.F.,Charlesworth Andrew,Lubsen Jacobus,Swedberg Karl,Remme Willem J.,Erhardt Leif,Di Lenarda Andrea,Komajda Michel,Metra Marco,Torp-Pedersen Christian,Poole-Wilson Philip A.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference18 articles.

1. How to assess new treatments for the management of heart failure;Cleland;Eur J Heart Fail,2002

2. Combined endpoints;Lubsen;Stat Med,2002

3. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure;Packer;J Card Fail,2002

4. Effects of candesartan on mortality and morbidity in patients with chronic heart failure;Pfeffer;Lancet,2003

5. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both;Pfeffer;N Engl J Med,2003

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond the classic major cardiovascular event outcome for cardiovascular trials;European Heart Journal;2024-07-31

2. Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction;European Heart Journal;2024-05-28

3. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial;Journal of the American College of Cardiology;2024-05

4. Utilizing Quality of Life Adjusted Days Alive and Out of Hospital in Heart Failure Clinical Trials;Circulation: Cardiovascular Quality and Outcomes;2024-05

5. Nature and Magnitude of the Benefits of Dapagliflozin and Empagliflozin for Heart Failure;Circulation;2024-03-12